COGNITION THERAPEUTICS INC Stock Price, News & Analysis

Cognition Therapeutics (NASDAQ: CGTX) presented promising results from their Phase 2 SHINE study of CT1812 in Alzheimer's disease patients at the CTAD conference. The study demonstrated significant cognitive benefits in patients with lower plasma p-tau217 levels, showing a 95% slowing of cognitive decline measured by ADAS-Cog 11 and a 108% slowing measured by MMSE. These results were observed in participants treated with CT1812 (pooled 100mg and 300mg doses).

Dr. Michael Woodward, presenting at CTAD, highlighted that these findings align with anti-amyloid immunotherapeutics' effectiveness in people with low p-tau. The company plans to discuss potential Phase 3 approaches with the FDA in an end-of-Phase 2 meeting.

Cognition Therapeutics (NASDAQ: CGTX) announced that Dr. Michael Woodward will present analyses from the Phase 2 'SHINE' trial of CT1812 in mild-to-moderate Alzheimer's disease at the CTAD conference in Madrid. The company reports positive results from the trial, highlighting consistent efficacy signals in patients treated with CT1812 for six months and a favorable tolerability profile. Additionally, the company will present baseline characteristics from the Phase 2 'SHIMMER' trial in DLB patients, focusing on symptoms like cognitive and movement impairment, fluctuating attention, and sleep disorder.

Cognition Therapeutics (NASDAQ: CGTX) has released a new episode of its "Conversations" video podcast titled "Executing Clinical Research in Dementia with Lewy Bodies (DLB)" during DLB Awareness Month. The episode features a panel of experts discussing:

• Similarities and differences between DLB and Alzheimer's disease
• Unique symptoms experienced by DLB patients
• Design of the SHIMMER study of CT1812 in mild-to-moderate DLB
• Importance of identifying clinical and functional benefit signals in DLB, which currently lacks approved disease-modifying therapies

The podcast is moderated by Cognition's CMO, Dr. Anthony Caggiano, and includes three leading experts in the field. It is available on the Cognition website under the Conversations tab, presented in three chapters covering comparisons between Alzheimer's and DLB, SHIMMER study design, and metrics for success in signal-finding studies.

Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company developing drugs for neurodegenerative disorders, announced its participation in the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024. The company's president and CEO, Lisa Ricciardi, will take part in a panel discussion titled Frontiers in Neuroscience.

Additionally, Ms. Ricciardi will host one-on-one investor meetings to discuss recent achievements and clinical development plans for CT1812, Cognition's lead candidate for treating Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. Interested investors can register for the conference through their Roth Capital Partners' sales representative.

Cognition Therapeutics supports Lewy Body Dementia Awareness Month, highlighting the need for improved treatments for dementia with Lewy bodies (DLB), the second most common form of progressive dementia. DLB affects approximately 1.4 million people in the U.S. with no approved treatments available. The company is advancing CT1812 in the Phase 2 'SHIMMER' clinical trial for DLB treatment, with data readout expected in Q4 2024.

DLB is caused by the buildup of alpha-synuclein protein, forming Lewy bodies inside neurons. Symptoms include impaired cognition, visual hallucinations, REM sleep behavior disorder, and movement issues. Cognition Therapeutics partnered with the Lewy Body Dementia Association (LBDA) and the University of Miami Miller School of Medicine to design the SHIMMER trial, which has enrolled 130 patients with mild-to-moderate DLB across the U.S.

The DLB community will convene at the first Externally Led Patient-Focused Drug Development (EL-PFDD) Meeting on October 15, 2024, where patients and care partners will share their experiences with the FDA.

Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company developing drugs for neurodegenerative disorders, announced its participation in two upcoming investor conferences in September 2024. CEO Lisa Ricciardi will attend the Chardan Capital Markets Leadership Call on September 5 and the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11.

The company recently presented results from the Phase 2 SHINE study, showing that their orally delivered CT1812 slowed the progression of mild-to-moderate Alzheimer's disease after six months of treatment. Cognition is advancing its clinical programs for CT1812 in Alzheimer's disease, with the SHIMMER Phase 2 study readout expected by year-end 2024. Archived webcasts of the presentations will be available on Cognition's investor relations site.

Cognition Therapeutics (NASDAQ: CGTX) has published results from the SEQUEL study of CT1812, their lead candidate for Alzheimer's disease treatment, in The Journal of Prevention of Alzheimer's Disease. The single-site study measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer's after 29 days of treatment. CT1812-treated participants showed consistent trends of improvement across all prespecified EEG parameters, with significant changes in relative theta power and AEC-c, which assesses brain region connectivity.

The study suggests CT1812 may normalize brain wave patterns and facilitate communication between brain regions by protecting synapses as an Aβ oligomer antagonist. Treatment produced a reduction in global relative theta power across various brain regions and improved global alpha AEC-c. CT1812 was well-tolerated with mostly mild to moderate adverse events reported.

Cognition Therapeutics (Nasdaq: CGTX) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo for CT1812 in mild-to-moderate Alzheimer's disease.

2. Topline results from SHIMMER study in mild-to-moderate DLB expected by year-end 2024.

3. Q2 2024 financials: $28.5 million in cash and cash equivalents, $57.3 million in remaining NIA grant funds.

4. R&D expenses increased to $11.6 million in Q2 2024 from $8.5 million in Q2 2023.

5. Net loss of $7.0 million ($0.18 per share) in Q2 2024 compared to $4.7 million ($0.16 per share) in Q2 2023.

6. Cash runway estimated into Q2 2025.

Cognition Therapeutics (Nasdaq: CGTX), a clinical-stage biopharmaceutical company, has announced it will release its Q2 2024 financial results on August 8, 2024, before market open. The company will host a conference call and live audio webcast at 8:30 a.m. ET on the same day to discuss the results and provide a business update.

Cognition Therapeutics focuses on developing treatments for neurodegenerative disorders. Their lead candidate, CT1812, is being investigated for Alzheimer's disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD). The company believes CT1812 and its pipeline of σ-2 receptor modulators can regulate impaired pathways in these diseases, offering a potentially distinct approach from other treatments in development.